Consort Medical plc announced that it has entered into a development agreement including key commercial supply terms with Regeneron Pharmaceuticals, Inc. The agreement provides for Consort's proprietary VapourSoft technology to be incorporated into a novel drug delivery device designed by Regeneron. In the event that Regeneron elects to commercialise the developed device, the parties will enter into a full commercial supply agreement with manufacturing to be undertaken by Consort for both the VapourSoft technology and the drug delivery device itself. VapourSoft is one of a range of novel technologies developed at Consort's Innovation Centre based in Cambridge, United Kingdom.

Through the use of a liquid gas propellant, rather than a spring to drive the delivery of the drug, VapourSoft facilitates delivery of a broader range of drug formulations and volumes.